Next Article in Journal
Bioactive ZnO Coatings Deposited by MAPLE—An Appropriate Strategy to Produce Efficient Anti-Biofilm Surfaces
Next Article in Special Issue
Determination of the Absolute Configurations of Chiral Drugs Using Chiroptical Spectroscopy
Previous Article in Journal
Comparison of Properties among Dendritic and Hyperbranched Poly(ether ether ketone)s and Linear Poly(ether ketone)s
Review

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Institute Pasteur Italy—Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Derek J. McPhee
Molecules 2016, 21(2), 221; https://doi.org/10.3390/molecules21020221
Received: 11 January 2016 / Revised: 4 February 2016 / Accepted: 8 February 2016 / Published: 16 February 2016
(This article belongs to the Special Issue Chiral Drugs)
Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains. This review exemplifies the various studies made to investigate the effect of chirality on the antiretroviral activity of top HIV-1 NNRTI compounds, such as nevirapine (NVP), efavirenz (EFV), alkynyl- and alkenylquinazolinone DuPont compounds (DPC), diarylpyrimidine (DAPY), dihydroalkyloxybenzyloxopyrimidine (DABO), phenethylthiazolylthiourea (PETT), indolylarylsulfone (IAS), arylphosphoindole (API) and trifluoromethylated indole (TFMI) The chiral separation, the enantiosynthesis, along with the biological properties of these HIV-1 NNRTIs, are discussed. View Full-Text
Keywords: chirality; HIV-1; reverse transcriptase; non-nucleoside inhibitor chirality; HIV-1; reverse transcriptase; non-nucleoside inhibitor
Show Figures

Graphical abstract

MDPI and ACS Style

Famiglini, V.; Silvestri, R. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Molecules 2016, 21, 221. https://doi.org/10.3390/molecules21020221

AMA Style

Famiglini V, Silvestri R. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Molecules. 2016; 21(2):221. https://doi.org/10.3390/molecules21020221

Chicago/Turabian Style

Famiglini, Valeria, and Romano Silvestri. 2016. "Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors" Molecules 21, no. 2: 221. https://doi.org/10.3390/molecules21020221

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop